Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system’s T cells to attack tumor cells. Their introduction a decade ago marked a major advance in cancer therapy, but only 10% to 30% of treated patients experience long-term improvement. New findings could now bolster the effectiveness of immune-checkpoint therapy.
Click here for original story, Researchers develop promising new cancer therapy
Source: ScienceDaily